uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
203 articles about uniQure
-
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
2/28/2024
uniQure N.V. reported its financial results for the fourth quarter and full year 2023 and highlighted recent progress across its business.
-
Gene therapy company uniQure announced Tuesday “ongoing evidence” of a clinical benefit for its Huntington’s disease treatment. However, investors were not impressed as the stock dropped nearly 20%.
-
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
12/19/2023
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated interim data including up to 30 months of follow-up from 39 patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington’s disease.
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 8, 2023
12/8/2023
uniQure N.V. today announced the grant of inducement equity awards to newly hired employees.
-
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseasePatient enrollment expected to begin in first half of 2024
11/29/2023
uniQure N.V. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-191, the Company’s gene therapy candidate for Fabry disease.
-
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
11/7/2023
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the third quarter of 2023 and highlighted recent progress across its business.
-
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
10/24/2023
uniQure N.V. announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy Annual Meeting being held October 24-27 in Brussels, Belgium.
-
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
10/5/2023
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced a strategic reorganization that will significantly reduce operating expenses while supporting focused execution to rapidly advance multiple clinical-stage programs to proof-of-concept.
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 02, 2023
10/2/2023
uniQure N.V. announced the grant of inducement equity awards to newly hired employees.
-
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe EpilepsyClinical trial initiation expected in the fourth quarter of 2023
9/5/2023
uniQure N.V. announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy.
-
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
8/1/2023
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.
-
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
6/26/2023
uniQure N.V. today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately.
-
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
6/21/2023
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced promising interim data, including up to 24 months of follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.
-
The Huntington’s disease space saw a flurry of activity Wednesday as PTC and uniQure released data from their respective mid-phase trials.
-
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
5/15/2023
uniQure N.V. announced it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX® to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million in cash.
-
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
5/9/2023
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the first quarter of 2023 and highlighted recent progress across its business.
-
Top 2023 Neurodegenerative Readouts
4/17/2023
Clinical results for experimental treatments in Alzheimer’s, ALS and more are expected over the coming months. BioSpace highlights a few of the more highly anticipated datasets. -
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 13, 2023
3/13/2023
uniQure N.V. today announced that the Company granted equity awards to 31 employees as a material inducement to commencing their employment.
-
uniQure to Participate in Multiple Upcoming Industry Conferences in March
3/2/2023
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences.
-
In its 2022 financial report Monday, uniQure provided updates on the progress of its Huntington’s disease and ALS programs.